Oncologists/Regimens Combining Immunotherapy and Chemo in India
Chemotherapy shrinks tumors, but cancer often finds a way back. Immunotherapy can train your own immune system to keep fighting, yet on its own it helps only some patients. That leaves a fair question: is there a doctor who can use both together?
Yes. Many oncologists in India now combine immunotherapy with chemotherapy, and the results in several cancers are strong. This guide shows who offers it, which regimens have the best evidence across cancer types, and how to pick a plan with your own doctor.
Key Takeaways
Chemo-immunotherapy pairs a checkpoint inhibitor, such as pembrolizumab, nivolumab, atezolizumab or durvalumab, with standard chemotherapy. Chemo damages cancer cells while the immunotherapy helps your immune system find and attack what remains.
Eight options are covered below, from a Hyderabad medical oncologist to seven trial-backed regimens for lung, breast, stomach and esophageal, cervical, biliary tract and head and neck cancers.
The right combination depends on your cancer type, stage and biomarkers such as PD-L1, EGFR and ALK, so testing comes before any treatment decision.
The Leading Chemo-Immunotherapy Options at a Glance
# | Option | Cancer type | Headline result | Treatment timing |
1 | Dr. Bharat Patodiya | Lung, stomach and other solid tumors | Plan built after biomarker testing | Individualized |
2 | Tata Memorial Centre Low-Dose Regimen | Recurrent or metastatic head and neck | Median OS 10.3 vs 6.2 months | Ongoing, with oral chemo |
3 | Pembrolizumab With Chemotherapy | Lung (non-small cell) | Median OS 22.0 vs 10.6 months (non-squamous, metastatic) | First-line, or before and after surgery |
4 | Pembrolizumab With Chemotherapy | Early triple-negative breast | pCR 64.8% vs 51.2% | Before and after surgery |
5 | Nivolumab With Chemotherapy | Stomach, gastroesophageal junction and esophageal adenocarcinoma | Median OS 14.4 vs 11.1 months (PD-L1 CPS 5 or higher) | First-line |
6 | Pembrolizumab With Chemotherapy | Advanced cervical (PD-L1 CPS 1 or higher) | Median OS 28.6 vs 16.5 months | First-line |
7 | Durvalumab With Chemotherapy | Advanced biliary tract | Median OS 13.0 vs 11.4 months | First-line |
8 | Atezolizumab With Chemotherapy | Extensive-stage small cell lung | Median OS 12.3 vs 10.3 months | First-line, then maintenance |
OS is overall survival, pCR is pathological complete response and CPS is combined positive score for PD-L1.
Oncologists and Regimens That Combine Immunotherapy With Chemotherapy
1. Dr. Bharat Patodiya
Dr. Bharat Patodiya is a medical oncologist in Hyderabad who treats lung, breast, gastrointestinal, liver and gallbladder, colorectal and blood cancers. His lung cancer care begins with molecular testing, which tells him whether a tumor suits immunotherapy, targeted drugs or a combination. You can read about his training and background before booking.
Three features that stand out:
Testing first: Molecular profiling guides the choice in advanced lung cancer.
Wide drug access: His practice covers atezolizumab, pembrolizumab and nivolumab, which are available in India.
Full-service care: Medical oncology services include PET-CT diagnostics and integrative care alongside drug therapy.
Good to know: His site notes that immunotherapy can be considered in stomach cancer when PD-L1 levels are high, and that it is used selectively in other cancers. Online consultations are available, which helps patients outside Hyderabad share reports before traveling.
Best for: Patients in or near Hyderabad who want a plan built around their own biomarkers.
2. Tata Memorial Centre Low-Dose Regimen
The Tata Memorial Centre Low-Dose Regimen pairs low-dose nivolumab with oral metronomic chemotherapy for recurrent or metastatic head and neck cancer. In the 422-patient TMC-I trial, median overall survival was 10.3 months versus 6.2 months with chemo alone.
Three features that stand out:
Better response: Objective response rate was 53.4% versus 24.1%.
Fewer severe side effects: Grade 3 or higher events were 37.1% versus 47.5%.
Lower cost: Reported drug cost was about $230 a month versus more than $1,000 a month for standard dosing.
Good to know: Experts point out that the comparison arm was not a standard first-line choice and that survival was lower than with first-line agents used in the US. Ask your oncologist whether this approach suits your situation or whether standard dosing is better.
Best for: Patients with advanced head and neck cancer where cost is a major limit.
3. Pembrolizumab With Chemotherapy for Lung Cancer
Pembrolizumab With Chemotherapy for Lung Cancer covers both metastatic and early-stage non-small cell lung cancer. Pembrolizumab With Chemotherapy for Lung Cancer covers both metastatic and early-stage non-small cell lung cancer. Metastatic patients without EGFR or ALK changes receive pemetrexed and platinum if non-squamous (KEYNOTE-189) or carboplatin and paclitaxel if squamous (KEYNOTE-407). Earlier-stage patients can receive it around surgery (KEYNOTE-671).
Three features that stand out:
Longer survival in metastatic disease: Median OS was 22.0 versus 10.6 months in KEYNOTE-189 and 17.2 versus 11.6 months in KEYNOTE-407.
Lasting benefit: Five-year survival was 19.4% versus 11.3% in KEYNOTE-189 and 18.4% versus 9.7% in KEYNOTE-407.
Surgery-stage gain: In KEYNOTE-671, five-year overall survival was 64.6% versus 53.6% (HR 0.74), and five-year event-free survival was 49.9% versus 26.5%.
Good to know: KEYNOTE-671 uses four cycles before surgery and up to 13 after, for resectable stage II-IIIB disease. Pemetrexed-platinum regimens can affect the kidneys, so expect regular kidney tests. Nivolumab is another option before surgery, with five-year survival of 65% versus 55% in CheckMate-816.
Best for: People with lung cancer at any stage who have no EGFR or ALK change.
4. Pembrolizumab With Chemotherapy for Triple-Negative Breast Cancer
Pembrolizumab With Chemotherapy for Triple-Negative Breast Cancer is the standard for early disease. KEYNOTE-522 showed that overall survival also improved, with a hazard ratio of 0.66.
Three features that stand out:
Higher complete response: pCR was 64.8% versus 51.2%.
Five-year gain: Five-year overall survival was 86.6% versus 81.7%.
Broad eligibility: Benefit held across PD-L1 subgroups.
Good to know: Treatment starts before surgery with chemotherapy and pembrolizumab, then continues after surgery for up to nine cycles. Your care team will watch for immune side effects such as thyroid changes throughout.
Suited to: Patients with stage II or III triple-negative breast cancer.
5. Nivolumab With Chemotherapy for Stomach and Esophageal Cancer
Nivolumab With Chemotherapy for Stomach and Esophageal Cancer is a first-line option for advanced gastric, gastroesophageal junction and esophageal adenocarcinoma. In CheckMate 649, patients received nivolumab with XELOX or FOLFOX chemotherapy.
Three features that stand out:
PD-L1 guided benefit: Median OS was 14.4 versus 11.1 months in patients with a PD-L1 CPS of 5 or higher (HR 0.70).
Benefit in all patients: Median OS was 13.8 versus 11.6 months across everyone randomized (HR 0.79).
Familiar chemo backbone: XELOX and FOLFOX are widely used oxaliplatin regimens.
Good to know: The most common serious side effects were low neutrophil counts (15%) and anemia (6%), so expect frequent blood tests. Ask for a PD-L1 CPS result first, since the gain is clearest at higher scores.
A fit for: Patients with advanced stomach, junction or esophageal adenocarcinoma and a higher PD-L1 score.
6. Pembrolizumab With Chemotherapy for Cervical Cancer
Pembrolizumab With Chemotherapy for Cervical Cancer is used for persistent, recurrent or metastatic disease. In the 617-patient KEYNOTE-826 trial, pembrolizumab was added to paclitaxel with cisplatin or carboplatin, with or without bevacizumab.
Three features that stand out:
Large survival gain: Median OS was 28.6 versus 16.5 months in patients with a PD-L1 CPS of 1 or higher (HR 0.60).
Even higher with high PD-L1: Median OS was 29.6 versus 17.4 months at a CPS of 10 or higher.
Short chemo course: Chemotherapy ran every three weeks for six cycles.
Good to know: Grade 3 or higher events occurred in 82.4% of patients on pembrolizumab versus 75.4% on chemo alone, so close monitoring matters. Bevacizumab was added at the doctor's discretion.
Ideal for: Women with advanced cervical cancer whose tumors have a PD-L1 CPS of 1 or higher.
7. Durvalumab With Chemotherapy for Biliary Tract Cancer
Durvalumab With Chemotherapy for Biliary Tract Cancer treats unresectable, locally advanced or metastatic bile duct and gallbladder cancers. The TOPAZ-1 trial combined durvalumab with gemcitabine and cisplatin, a long-standing chemo pair for these cancers.
Three features that stand out:
Longer survival: Median OS was 13.0 versus 11.4 months (HR 0.75).
Lasting effect: Three-year survival was 15.0% versus 7.6%.
Wide coverage: The trial included intrahepatic and extrahepatic bile duct cancer and gallbladder cancer.
Good to know: Durvalumab is given every three weeks with gemcitabine and cisplatin on days 1 and 8. Biliary cancers are hard to treat, so ask about genetic testing for targeted drugs that may apply alongside or after this regimen.
Works well for: Patients with advanced bile duct or gallbladder cancer who can receive gemcitabine and cisplatin.
8. Atezolizumab With Chemotherapy for Small Cell Lung Cancer
Atezolizumab With Chemotherapy for Small Cell Lung Cancer is an FDA-approved first-line option for extensive-stage disease, approved on March 18, 2019. IMpower133 combined atezolizumab with carboplatin and etoposide.
Three features that stand out:
Longer survival: Median OS was 12.3 versus 10.3 months (HR 0.70).
Slower progression: Median progression-free survival was 5.2 versus 4.3 months.
Clear schedule: Up to four cycles of the combination, then atezolizumab alone.
Good to know: Atezolizumab 1,200 mg is given every three weeks, and later infusions can shorten to 30 minutes if the first ones go well. Maintenance continues until the cancer progresses or side effects become too hard to manage.
Best suited to: Patients with newly diagnosed extensive-stage small cell lung cancer.
How to Choose the Right Chemo-Immunotherapy Plan
Four quick steps help you and your doctor settle on the right plan.
Step:1 Get the Right Biomarker Tests
Ask your oncologist to order biomarker testing before any drug is chosen.
Request the tests that match your cancer:
PD-L1 score for lung, stomach and cervical cancer
EGFR and ALK status for lung cancer
MSI-H or dMMR status for gastrointestinal and gynecologic tumors
Hormone receptor and HER2 status for breast cancer
Testing shows whether immunotherapy is likely to help. A 2024 meta-analysis in Frontiers in Immunology found no significant gain for never-smokers or EGFR-positive lung cancer patients, so this step protects you from paying for a drug that may add little.
Step:2 Match the Regimen to Your Cancer and Stage
Ask your doctor which trial supports the suggested regimen.
Then confirm three things:
Your cancer type matches the trial
Your treatment timing (before surgery, after surgery or metastatic) matches
Your biomarker result meets the eligibility rule
Matching these ensures the survival numbers you read actually apply to you.
Step:3 Weigh Benefits Against Side Effects
Ask how your team will watch for immune-related side effects.
Agree on what to report right away:
Rash or itching
Diarrhea or belly pain
New cough or breathlessness
Fever or unusual tiredness
In a meta-analysis of five lung cancer trials, chemo-immunotherapy improved survival (HR 0.68) and also raised immune-related events (odds ratio 2.78). Reporting symptoms early keeps those events manageable.
Step:4 Check Cost and Access
Ask for a written cost estimate for the full course, not just the first cycle.
Then look for ways to lower it:
Hospital or manufacturer patient-assistance programs
Insurance or Ayushman Bharat eligibility, confirmed directly
Lower-dose options such as the Tata Memorial approach, where suitable
Your clinic's patient resources
Knowing the full cost early helps you plan the whole course so treatment is not interrupted midway.
Conclusion
Chemo-immunotherapy is a proven option for several cancers, and India now has specialists and regimens to match. Before your first appointment, gather your pathology report, biomarker results and scans, and write down three questions: which regimen fits my cancer, what side effects should I report at once, and what is the plan if it stops working. If you are looking for an independent consultation, you can contact Dr. Patodiya's clinic or any qualified oncologist, and his experience with novel drugs page is a useful read first.
Frequently Asked Questions
Does immunotherapy replace chemotherapy?
Not always. In many regimens above, both are given together, and some patients later continue on immunotherapy alone.
Can side effects appear after treatment ends?
Yes. Immune-related side effects can occur at any time, even after the last dose, so report new symptoms such as rash, diarrhea or breathlessness quickly.
Who should be cautious about immunotherapy?
People with autoimmune disease, an organ or allogeneic transplant, or pregnancy need a careful review before starting.
Is there an injection version of pembrolizumab or nivolumab?
Subcutaneous forms (Keytruda Qlex and Opdivo Qvantig) are FDA-approved in the US. Ask your oncologist whether they are available in India.
How long does chemo-immunotherapy last?
It depends on the regimen. Pre-surgery courses can be three to four cycles, while maintenance can continue until the cancer progresses.
Do I need a second opinion?
A second opinion is reasonable for any complex plan. Bring your reports so the second doctor can confirm the regimen and biomarker choice.
Sources
Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials - PMC - pmc.ncbi.nlm.nih.gov
Immunotherapy Expands Lung Cancer Treatment Options - NCI - www.cancer.gov
Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery | UT MD Anderson - www.mdanderson.org
Comments